In support of this, we found that optimal treatment of aged hMSCs with the SIRT1 agonist SRT1720 enhanced cell survival in cultured cells under conditions of hypoxia and oxidative stress that mimic in part the conditions of ischemia and reperfusion that are present during MI in vivo. This evidence concerns the gene SIRT1 and myocardial infarction.